Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 11

Trial Status

Other2

Role Distribution

Principal Investigator2
PI Rate100%

Activity Timeline

Clinical Trials (2)

NCT03656835Not ApplicableActive Not Recruiting
Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma Germinal Center B-Cell TypeDiffuse Large B-Cell Lymphoma, Not Otherwise Specified+1 more
PrincipalinvestigatorStart date: 2018-09-26
NCT02992522Phase 1Active Not Recruiting
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
B-CellB-Cell Lymphoma, UnspecifiedGrade 1 Follicular Lymphoma+10 more
PrincipalinvestigatorStart date: 2017-02-21

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Mitchell S Cairo, MD

New York Medical College

Related
13 trials

Shared therapeutic areas:

Lymphoma, Large B-Cell, DiffuseHigh Grade B-Cell Lymphoma

Worked with same sponsors:

Celgene
Similarity Score4%

Brenda Sandmaier

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Related
12 trials

Shared therapeutic areas:

Recurrent Marginal Zone LymphomaLymphoma, Large B-Cell, Diffuse
Similarity Score4%

Elias Jabbour, MD

M.D. Anderson Cancer Center

Related
15 trials

Shared therapeutic areas:

Recurrent Burkitt LymphomaRefractory Burkitt Lymphoma
Similarity Score4%

Jae Park, MD

Memorial Sloan Kettering Cancer Center

Related
17 trials

Shared therapeutic areas:

Lymphoma, Large B-Cell, Diffuse

Worked with same sponsors:

Genentech, Inc.
Similarity Score2%

Roberto Hernández Martín, MD

Hospital Virgen de la Concha

Related
2 trials

Shared therapeutic areas:

Lymphoma, Large B-Cell, Diffuse
Similarity Score2%

Elena Pérez Ceballos, MD

Hospital Morales Meseguer

Related
2 trials

Shared therapeutic areas:

Lymphoma, Large B-Cell, Diffuse
Similarity Score2%

Ryotaro Nakamura

City of Hope Medical Center

Related
10 trials

Shared therapeutic areas:

Recurrent Marginal Zone Lymphoma
Similarity Score2%

Qifa Liu

Nanfang Hospital, Southern Medical University

Related
33 trials

Shared therapeutic areas:

Lymphoma, Large B-Cell, Diffuse
Similarity Score2%

Sarit Assouline, MD

Jewish General Hospital

Related
5 trials

Shared therapeutic areas:

Lymphoma, Large B-Cell, Diffuse
Similarity Score2%

Thomas E. Witzig, MD

Mayo Clinic

Related
12 trials

Shared therapeutic areas:

Lymphoma, Large B-Cell, Diffuse
Similarity Score2%

Publications (0)

No publications found for this investigator.

Clinical Trials (2)

Showing 2 of 2 trials

NCT03656835Not ApplicablePrincipalInvestigator

Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma Germinal Center B-Cell TypeDiffuse Large B-Cell Lymphoma, Not Otherwise Specified+1 more
Active Not Recruiting
NCT02992522Phase 1PrincipalInvestigator

Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

B-CellB-Cell Lymphoma, UnspecifiedGrade 1 Follicular Lymphoma+10 more
Active Not Recruiting

All 2 trials loaded